Latest MorphoSys AG Stories
Results Show Durable Responses in High Risk Patient Population MARTINSRIED, Germany, MUNICH and MONROVIA, Calif., Dec.
MARTINSRIED, Germany, Nov. 13, 2008 (GLOBE NEWSWIRE) -- MorphoSys AG (Frankfurt:MOR) (Prime Standard Segment, TecDAX) announced today the publication of preclinical data from its most advanced proprietary drug development program MOR103, a fully human HuCAL antibody directed against GM-CSF.
MARTINSRIED, Germany, Sept.
MARTINSRIED, Germany, July 23, 2008 (PRIME NEWSWIRE) -- MorphoSys AG (Frankfort:MOR) (Prime Standard Segment, TecDAX) announced today that Astellas Pharma Inc.
MARTINSRIED, Germany, July 17, 2008 (PRIME NEWSWIRE) -- MorphoSys AG (FSE:MOR) (Prime Standard Segment, TecDAX) announced today that Phadia AB, a world leader in autoimmunity and allergy testing, has implemented a series of HuCAL-based recombinant antibodies in its marketed autoimmune tests Varelisa(tm) and EliA(tm).
- Withering but not falling off, as a blossom that persists on a twig after flowering.